Impaired c-Fos and Polo-Like Kinase 2 Induction in the Limbic System of Fear-conditioned α-Synuclein Transgenic Mice

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Schell, Heinrich ^a,b   Boden, Cindy ^b   Chagas, André Maia ^b   Kahle, Philipp J ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; POLO LIKE KINASE 2; PROTEIN C FOS; SERINE;

AGE; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; BRAIN REGION; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; FEAR; GENE PRODUCT; HIPPOCAMPUS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIMBIC SYSTEM; MALE; MOUSE; NERVE CELL; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PERIKARYON; TRANSGENIC MOUSE; UPREGULATION;

ALPHA-SYNUCLEIN; AMYGDALA; AMYLOIDOSIS; ANIMALS; COGNITION DISORDERS; COHORT STUDIES; CONDITIONING, CLASSICAL; FEAR; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; LIMBIC SYSTEM; MALE; MICE; MICE, TRANSGENIC; NEURONAL PLASTICITY; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-FOS; SILVER STAINING; SYNAPSES; SYNAPTIC TRANSMISSION; TIME FACTORS;

MUS MUSCULUS;

EID: 84870261823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050245     Document Type: Article

References (36)

1. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, et al. (1997) α-Synuclein in Lewy bodies. Nature 388: 839-840.
2. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y, (2010) Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 25Suppl 1: S78-S82.
3. Jellinger KA, (2003) α-Synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 106: 191-201.
4. Lim Y, Kehm VM, Lee EB, Soper JH, Li C, et al. (2011) α-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 31: 10076-10087.
5. Tanji K, Mori F, Mimura J, Itoh K, Kakita A, et al. (2010) Proteinase K-resistant α-synuclein is deposited in presynapses in human Lewy body disease and A53T α-synuclein transgenic mice. Acta Neuropathol 120: 145-154.
6. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
7. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
8. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
9. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L, (2003) Caught in the act: α-synuclein is the culprit in Parkinson's disease. Neuron 40: 453-456.
10. Kahle PJ, (2008) α-Synucleinopathy models and human neuropathology: similarities and differences. Acta Neuropathol 115: 87-95.
11. Freichel C, Neumann M, Ballard T, Müller V, Woolley M, et al. (2007) Age-dependent cognitive decline and amygdala pathology in α-synuclein transgenic mice. Neurobiol Aging 28: 1421-1435.
12. Price DL, Rockenstein E, Ubhi K, Phung V, MacLean-Lewis N, et al. (2010) Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of α-synucleinopathy-implications for excitotoxicity. PLoS One 5: e14020.
13. Kahle PJ, Neumann M, Ozmen L, Müller V, Jacobsen H, et al. (2000) Subcellular localization of wild-type and Parkinson's disease-associated mutant α-synuclein in human and transgenic mouse brain. J Neurosci 20: 6365-6373.
14. Kahle PJ, Neumann M, Ozmen L, Müller V, Odoy S, et al. (2001) Selective insolubility of α-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159: 2215-2225.
15. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, et al. (2002) Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J Clin Invest 110: 1429-1439.
16. Schell H, Hasegawa T, Neumann M, Kahle PJ, (2009) Nuclear and neuritic distribution of serine-129 phosphorylated α-synuclein in transgenic mice. Neuroscience 160: 796-804.
17. Milanovic S, Radulovic J, Laban O, Stiedl O, Henn F, et al. (1998) Production of the Fos protein after contextual fear conditioning of C57BL/6N mice. Brain Res 784: 37-47.
18. Dewachter I, Filipkowski RK, Priller C, Ris L, Neyton J, et al. (2009) Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging 30: 241-256.
19. Lelos MJ, Good MA, (2012) c-Fos expression reveals aberrant neural network activity during cued fear conditioning in APPswe transgenic mice. Neurobiol Learn Mem 98: 1-11.
20. Kauselmann G, Weiler M, Wulff P, Jessberger S, Konietzko U, et al. (1999) The polo-like protein kinases Fnk and Snk associate with a Ca2+- and integrin-binding protein and are regulated dynamically with synaptic plasticity. EMBO J 18: 5528-5539.
21. Seeburg DP, Sheng M, (2008) Activity-induced Polo-like kinase 2 is required for homeostatic plasticity of hippocampal neurons during epileptiform activity. J Neurosci 28: 6583-6591.
22. Inglis KJ, Chereau D, Brigham EF, Chiou SS, Schöbel S, et al. (2009) Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system. J Biol Chem 284: 2598-2602.
23. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, et al. (2010) Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem 285: 2807-2822.
24. LeDoux JE, (2000) Emotion circuits in the brain. Annu Rev Neurosci 23: 155-184.
25. Maren S, (2001) Neurobiology of Pavlovian fear conditioning. Annu Rev Neurosci 24: 897-931.
26. Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, et al. (2009) α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet 41: 308-315.
27. Gureviciene I, Gurevicius K, Tanila H, (2009) Aging and α-synuclein affect synaptic plasticity in the dentate gyrus. J Neural Transm 116: 13-22.
28. Kurz A, Double KL, Lastres-Becker I, Tozzi A, Tantucci M, et al. (2010) A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice. PLoS One 5: e11464.
29. Diógenes MJ, Dias RB, Rombo DM, Vicente Miranda H, Maiolino F, et al. (2012) Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 32: 11750-11762.
30. Martin ZS, Neugebauer V, Dineley KT, Kayed R, Zhang W, et al. (2012) α-Synuclein oligomers oppose long-term potentiation and impair memory through a calcineurin-dependent mechanism: relevance to human synucleopathic diseases. J Neurochem 120: 440-452.
31. Samson RD, Paré D, (2005) Activity-dependent synaptic plasticity in the central nucleus of the amygdala. J Neurosci 25: 1847-1855.
32. Goers J, Manning-Bog AB, McCormack AL, Millett IS, Doniach S, et al. (2003) Nuclear localization of α-synuclein and its interaction with histones. Biochemistry 42: 8465-8471.
33. Pronin AN, Morris AJ, Surguchov A, Benovic JL, (2000) Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J Biol Chem 275: 26515-26522.
34. Okochi M, Walter J, Koyama A, Nakajo S, Baba M, et al. (2000) Constitutive phosphorylation of the Parkinson's disease associated α-synuclein. J Biol Chem 275: 390-397.
35. Braithwaite SP, Stock JB, Mouradian MM, (2012) alpha-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Rev Neurosci 23: 191-198.
36. Nemani VM, Lu W, Berge V, Nakamura K, Onoa B, et al. (2010) Increased expression of α-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 65: 66-79.